- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00621556
Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
- To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography
- To demonstrate that RG1068-enhanced MRCP improves detection and characterization of intraductal papillary mucinous neoplasms (IPMN) relative to unenhanced MRCP in patients with suspected IPMN
- To correlate findings on MRCP with histologically confirmed malignancy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Until relatively recently, endoscopic retrograde cholangiopancreatography (ERCP) was the primary diagnostic and therapeutic modality for assessing patients with suspected pancreatic disease or abnormalities. However, this invasive procedure carries with it a significant potential for complications including acute pancreatitis, hemorrhage and infection, as well as reactions to contrast material or premedications and exposure to radiation. In addition, the success of such procedures, both from the standpoint of safety and efficacy, is highly dependent on the skill of the endoscopist, and the cost of ERCP is relatively high.
The advent of magnetic resonance imaging has resulted in the development of a less expensive, non-invasive, radiation-free means of assessing the pancreaticobiliary system: Magnetic Resonance Cholangiopancreatography (MRCP). MRCP uses stationary water in biliary and pancreatic secretions as an intrinsic contrast medium, thus facilitating examination of pancreatic and biliary ducts and surrounding tissue. Secretin, which promotes the secretion of pancreatic fluid into the pancreatic ducts, can thereby enhance the MR imaging signal, improving delineation of both normal and abnormal structures, as well as highlighting abnormal fluid collections and leakage. Conversely, filling defects can indicate the presence of stones or mass lesions.
This study is being undertaken to prospectively assess the effectiveness of RG1068-enhanced MRCP relative to unenhanced MRCP for the evaluation of patients with known or suspected IPMN. RG1068 is a synthetic human secretin with a pharmacological profile very similar to that of biological and synthetic porcine secretins. Secretin is a 27-amino acid gastrointestinal peptide hormone that is produced by S-cells in the duodenum in response to the pH decrease caused by the passage of partially digested food from the stomach into the intestine. RG1068 is identical in amino acid sequence to naturally occurring human secretin and differs from porcine secretin in 2 amino acids.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females older than 18 years of age
- Is clinically indicated for MRCP of the pancreas based on prior imaging features suggestive or suspicious of IPMN (eg. Cystic lesion in the pancreas along the duct, ductal dilatation)
- Scheduled for MRCP and therapeutic or diagnostic ERCP or surgery for the IPMN
- Has been fully informed and has personally signed and dated the Written Informed Consent and Health Insurance Portability Accountability Act (HIPAA) provisions
- Is a male, or is a female not of childbearing potential, or is a female of childbearing potential who is using effective contraception and has a negative serum pregnancy test on the same day, but prior to, study drug administration
- Is able and willing to complete all study procedures specified in the protocol
Exclusion Criteria:
- Presence of a pancreatic stent
- History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease which, in the opinion of the investigator, precludes study participation
- History of sensitivity to any of the ingredients in the study drug
- Pregnancy
- Any contraindication to MRI procedure, including but not limited to implanted metal devices (e.g., pacemaker, aneurysm clips, cochlear implants)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Drug + MR with MRCP
|
Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MR & MRCP - Images will be evaluated for quality, main and branch duct visualization, ductal diameter and improved visualization of structural abnormalities with and without use of RG1068.
Time Frame: 1
|
1
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Laboratory
Time Frame: 2
|
2
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Neoplasms
- Pancreatic Neoplasms
- Pancreatic Intraductal Neoplasms
- Physiological Effects of Drugs
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Secretin
Other Study ID Numbers
- 2006P002500
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intraductal Papillary Mucinous Neoplasms
-
Indiana UniversityCompletedIntraductal Papillary Mucinous NeoplasmUnited States
-
Helsinki University Central HospitalCompletedIntraductal Papillary Mucinous NeoplasmSweden, Finland
-
Zhejiang UniversityThe Second Hospital of Hebei Medical University; Huizhou Municipal Central... and other collaboratorsRecruitingIntraductal Papillary Mucinous NeoplasmChina
-
Boston Scientific CorporationActive, not recruitingIntraductal Papillary Mucinous NeoplasmUnited States, Netherlands, China, India, Japan, Sweden
-
University of California, San FranciscoRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Diseases | Pancreatic Ductal Adenocarcinoma | Pancreatic Cyst | Intraductal Papillary Mucinous Neoplasm | Mucinous Cyst | Pancreatic Intraductal Papillary Mucinous NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingPancreatic Carcinoma | Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-TypeUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Cancer Institute (NCI)RecruitingPancreatic Adenocarcinoma | Cholangiocarcinoma | Pancreatic Ductal Adenocarcinoma | Acinar Cell Carcinoma | Ampulla of Vater Adenocarcinoma | Periampullary Adenocarcinoma | Duodenal Adenocarcinoma | Pancreatic Intraductal Papillary Mucinous NeoplasmUnited States
-
Seoul National University HospitalCompletedIntraductal Papillary Mucinous Neoplasm | Pancreas CystKorea, Republic of
-
Indiana UniversityCompletedPancreatic Cyst | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Cystadenoma, Mucinous | Papillary Mucinous Cystadenoma, Borderline MalignancyUnited States
-
Fujian Provincial HospitalFirst Affiliated Hospital of Fujian Medical University; Fujian Medical University...UnknownBile Duct Neoplasms | Intraductal Papillary Mucinous NeoplasmChina
Clinical Trials on RG1068 (Synthetic Human Secretin)
-
Columbia UniversityWithdrawn
-
Massachusetts General HospitalTerminatedChronic PancreatitisUnited States
-
Indiana University School of MedicineRepligen Corporation; Shekhar, Anantha M.D., Ph.D.CompletedObsessive Compulsive Disorder (OCD)United States
-
University Hospitals Cleveland Medical CenterRepligen CorporationWithdrawnPancreas CancerUnited States
-
Massachusetts General HospitalTerminatedChronic Pancreatitis | Acute Recurrent PancreatitisUnited States
-
Repligen CorporationCompleted
-
Columbia UniversityWithdrawnPancreatic CancerUnited States
-
Repligen CorporationCompleted
-
Repligen CorporationTerminated
-
Elizabeth HechtCompletedPancreatic CancerUnited States